Compare NXRT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.1M | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | NXRT | COLL |
|---|---|---|
| Price | $28.14 | $48.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $36.33 | ★ $47.50 |
| AVG Volume (30 Days) | 171.2K | ★ 550.4K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $253,196,000.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | $2.45 | $3.67 |
| P/E Ratio | ★ N/A | $30.35 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $27.92 | $23.23 |
| 52 Week High | $45.19 | $49.92 |
| Indicator | NXRT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 66.37 |
| Support Level | $27.92 | $47.83 |
| Resistance Level | $29.25 | $49.92 |
| Average True Range (ATR) | 0.81 | 1.38 |
| MACD | -0.21 | -0.23 |
| Stochastic Oscillator | 11.10 | 72.20 |
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.